Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease – should one consider disease location? Authors’ reply
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- October 2016
has subject area
- 1103 Clinical Sciences (FoR)
- 1115 Pharmacology and Pharmaceutical Sciences (FoR)
- Adalimumab (MeSH)
- Antibodies, Monoclonal (MeSH)
- Antibodies, Monoclonal, Humanized (MeSH)
- Crohn Disease (MeSH)
- Gastroenterology & Hepatology (Science Metrix)
- Humans (MeSH)
- Infliximab (MeSH)